NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.Nurix and Sanofi first established a strategic collaboration in 2019 to develop and commercialize a portfolio of targeted protein degradation therapies for patients with complex diseases across various therapeutic areas. The partnership utilizes NRIX’s proprietary DEL-AI discovery platform to discover small molecules that promote the degradation of three initially designated drug targets. In 2021, Sanofi exercised its option to expand the number of targets from three to five.The latest update further expands the collaboration agreement between Nurix and Sanofi, highlighting the strength of its DEL-AI platform.Year to date, NRIX stock has plunged 39.6% against the industry’s 1.2% growth.Image Source: Zacks Investment ResearchDetails of NRIX’s Updated Collaboration Deal With SNYNurix's proprietary DEL-AI platform has enabled the discovery of novel binders, leading to the development of both targeted protein degraders and stand-alone binders for a previously untreatable transcription factor. Per management, this key target plays a crucial role in regulating proinflammatory cytokines and inflammation in autoimmune diseases, highlighting the potential of targeted protein degradation as an innovative therapeutic approach.Under the revised collaboration, Nurix will utilize its DEL-AI drug discovery platform to develop novel agents that leverage E3 ligases for targeted protein degradation. Sanofi holds the right to license drug candidates emerging from this research, while Nurix retains the option to co-develop and co-promote up to two future products in the United States after demonstrating clinical proof of concept in dosing, efficacy, and safety studies.For programs where Nurix exercises this option, both companies will share U.S. profits and losses equally, with NRIX also earning royalties on ex-U.S. sales. If the company chooses not to co-develop a program, it will receive milestone payments and royalties based on global development and sales from SNY.Nurix has received a license extension fee of $15 million from Sanofi. The company remains eligible for up to $465 million in potential development, regulatory, and commercial milestone payments per licensed program, along with royalties on future sales.Nurix Therapeutics, Inc. Price and Consensus Nurix Therapeutics, Inc. price-consensus-chart | Nurix Therapeutics, Inc. QuoteNRIX’s Zacks Rank & Other Stocks to ConsiderNurix currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks from the sector are Bayer BAYRY and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.In the past 30 days, estimates for Bayer’s earnings per share have increased from $1.14 to $1.19 for 2025. During the same time, earnings per share have increased from $1.23 to $1.28 for 2026. Year to date, shares of Bayer have gained 19.5%.BAYRY’s earnings matched estimates in two of the trailing three quarters while missing the same on the remaining occasion, the average negative surprise being 19.61%.In the past 30 days, the estimate for Corcept Therapeutics’ 2025 earnings per share has increased from $1.84 to $1.87. The estimate for 2026 earnings per share has increased from $3.05 to $3.11. Year to date, shares of Corcept Therapeutics have gained 66.3%.CORT’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 20.08%.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Nurix Therapeutics, Inc. (NRIX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks